BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Menarini Group's Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA)

lacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line...

August 21, 2022 | News

Sirnaomics Commence Treatment of Facial Squamous Cell Skin Cancer In Situ

Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi t...

August 19, 2022 | News

Innovent Biologics and Sanofi Enter Strategic Collaboration to Accelerate Development of Oncology Medicines and Expand Presence in China

Collaboration to accelerate the development and access of oncology medicines for cancer patients in China Clinical trial programs combining two of ...

August 05, 2022 | News

BioMed X Institute and Healthcare Business of Merck KGaA, Darmstadt, Germany, Start New Research Project in Oncology

Research team ‘EDC’ will study ‘Extrachromosomal DNA in Cancer’. With this project, the two partners launch their ninth collabor...

August 02, 2022 | News

BAMF Health and Telix complete first total-body PET scans with Illuccix for prostate cancer imaging

The PSMA-PET[1] imaging agent Illuccix® from Telix Pharmaceuticals Limited (Telix) has been used in combination with the uEXPLORER®, a first-o...

July 28, 2022 | News

DS-7300 Phase 2 Trial Initiated in Patients with Pretreated Extensive-Stage Small Cell Lung Cancer

Lung cancer is the second most common cancer and the leading cause of cancer-related deaths worldwide, with up to 14% being classified as SCLC in the U.S.1...

July 22, 2022 | News

AI-based Cancer Solution Pioneer Lunit Makes Market Debut

Lunit expects to raise approximately KRW 36.4 billion (US$ 28 million). Lunit intends to use the proceeds for R&D of its new AI products and ...

July 22, 2022 | News

Oncoshot Enters Collaboration Agreement With Omico

Oncoshot has just entered into a collaboration agreement with Omico, the Australian Genomic Cancer Medicine Centre. The respective parties were represented...

July 20, 2022 | News

miR Scientific announce the commercial availability of the miR Sentinel™ Prostate Cancer Test

miR Sentinel™ is a novel, urine-based, molecular test that analyzes small non-coding RNA using a proprietary biostatistical algorithm. The miR Sentin...

July 14, 2022 | News

GenomOncology Selected by Personalis to Support MRD and SNV Analysis for NeXT Personal™ Assay

NeXT Personal delivers industry-leading sensitivity to detect MRD and cancer recurrence at the earliest timepoints. The assay tracks and annotates individu...

July 13, 2022 | News

ZIRCON Phase III Kidney Cancer Imaging Study Completes Enrolment

TLX250-CDx, which has received "Breakthrough Designation" from the U.S. Food and Drug Administration (FDA)1, is being developed as an imaging agent for use...

July 11, 2022 | News

Bumrungrad International Hospital, Southeast Asia's Largest Hospital to Deploy Lunit's AI Cancer Screening System

Lunit and FujiFilm Thailand to supply Lunit INSIGHT CXR and Lunit INSIGHT MMG to one of SEA's largest hospital using Microsoft Azure Aim to detect cance...

July 05, 2022 | News

Seoul National University Hospital selects RayCare to advance oncology system

In April 2022 the carbon ion center at SNUH ordered RayStation treatment planning system, for use with their Toshiba Heavy Ion Therapy System. Th...

July 04, 2022 | News

GSK's Zejula (niraparib) Tablet approved in Singapore for first-line and recurrent monotherapy maintenance treatment in advanced ovarian cancer

GlaxoSmithKline (GSK) Singapore today announced that Health Sciences Authority has approved Zejula (niraparib) Tablet, an oral, on...

June 29, 2022 | News

Stay Connected